Telehealth Satisfaction and Self-Assessment for Rheumatoid Arthritis
This observational study, called "Telehealth-delivered HealthcaRe to ImproVe Care," is looking at how satisfied patients are with their telehealth visits and how well patients with rheumatoid arthritis (RA) can assess their own joints. If you have RA, are 19 or older, and can read English or Spanish, you might be able to participate. The study involves completing a survey about your telehealth visit satisfaction and, for RA patients, using an app called ArthritisPower to self-assess your joints before an in-office visit. Researchers want to see if your joint assessment matches your doctor's. The study aims to enroll 1580 participants, but its current status is unclear.
- Study design
- This is an observational study with a planned enrollment of 1580 participants. It is not a drug trial but focuses on evaluating healthcare processes.
- What's involved
- You would complete a telehealth satisfaction survey after your virtual visit. If you have RA, you would also use the ArthritisPower app to self-assess your joints before an in-office visit.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, correlation between patient and provider joint counts, is measured immediately after the intervention.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Telehealth-delivered HealthcaRe to ImproVe Care
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Correlation between patient joint count and provider joint countImmediately after the intervention
The investigators will examine and compare the patient and rheumatology provider's tender and swollen joint count summed scores and Pearson and Spearman's correlation coefficient (if the data is non-normally distributed). The investigators will also calculate a typical Clinical Disease Index (CDAI) for RA which is a composite score of TJC28 + SJC28 + Patient Global + Provider Global and correlate with the patient \[p\] CDAI (\[p\]TJC28 + \[p\]SJC28 + Patient Global + Provider Global). Disease remission for RA is denoted by a CDAI composite score of less than or equal to 2.8 while high RA disease activity is denoted by a CDAI score of 22 or greater. The investigators will also compute weighted kappa statistics, comparing the 4x4 table of remission, low moderate, and high disease activity categories, using the traditional CDAI cut points (2.8, 10, and 22).